Chemical Property of Xibrom
Chemical Property:
- Vapor Pressure:1.77E-13mmHg at 25°C
- Melting Point:268-270°C (dec.)
- Boiling Point:562.2ºC
- Flash Point:293.8ºC
- PSA：80.39000
- Density:1.565 g/cm3
- LogP:3.47060
- Storage Temp.:Refrigerator
- Hydrogen Bond Donor Count:5
- Hydrogen Bond Acceptor Count:11
- Rotatable Bond Count:6
- Exact Mass:765.99364
- Heavy Atom Count:45
- Complexity:361
- Purity/Quality:
-
99.9% *data from raw suppliers
BromfenacSodiumSesquihydrate *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)[O-].O.O.O.[Na+].[Na+]
- Recent ClinicalTrials:Bromfenac Versus Dexamethasone After Cataract Surgery
- Recent EU Clinical Trials:Effectiveness of Periocular drug Injection in CATaract surgery
- Recent NIPH Clinical Trials:The effect and the safety with0.1% bromfenac sodium hydrate ophthalmic solution and 0.1% betamethasone sodium phosphate ophthalmic solution in patients with diabetic macular edema.
-
Description
Duract was launched in the US as a potent, orally-active, long lasting peripheral
analgesic with antiinflammatory properties. It is structurally similar to ketoprofen and
diclofenac and can be prepared in three steps from 2-amino-4’-bromophenone using
Gassman’s oxindole synthesis. Duract’s biological effects are a result of its ability to
reduce prostaglandin production through inhibition of cyclooxygenase. As a 4-bromo
derivative of Amfenac, this modification increased the duration of analgesic activity
and antiinflammatory potency. It was also free of any CNS, cardiovascular or
autonomic effects. In comparison, 5 mg of Duract was equipotent to 650 mg of ASA
and 25 mg was slightly more potent than 400 mg of Ibuprofen.
-
Uses
Bromfenac (Xibrom, ISTA Pharmaceuticals, Irvine, USA; Bronuck, Senju Pharmaceutical, Osaka, Japan) is indicated for the treatment of postoperative inflammation and the reduction of ocular pain in patients after undergoing cataract extraction. For this task, one drop of Xibrom may be applied to the affected eye twice daily beginning 24 hours after cataract surgery and continuing for the first 2 weeks of the postoperative period. The clinical safety and efficacy of bromfenac have been extensively studied in diverse comparative investigations, including the treatment of external or anterior ocular inflammatory diseases, allergic conjunctivitis, scleritis, and postoperative inflammation.The results of two phase III multicenter, randomized double-masked placebo-controlled clinical trials showed that bromfenac ophthalmic solution 0.09% was effective in the rapid resolution of ocular pain after cataract surgery, and there was a statistically significant difference between the bromfenac and placebo groups demonstrated in these phase III clinical trials. Bromfenac is a non-steroidal anti-inflammatory agent.
